Skip to main content

Vanderbilt Vaccine Center Archives

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

Nov. 10, 2022—On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

Read more


Study finds Moderna’s COVID-19 vaccine safe and effective for young children

Nov. 4, 2022—A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

Read more


Event to spotlight VUMC’s COVID-19 research efforts

Nov. 3, 2022—The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

Read more


Vanderbilt’s Crowe receives the Building the Foundation Award from Research!America

Oct. 6, 2022—Vanderbilt's James Crowe Jr., MD, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization.

Read more


COVID antibody research conducted at VUMC lands national award

Aug. 24, 2022—A long-acting antibody combination discovered at Vanderbilt University Medical Center that protects against COVID-19 in high-risk individuals has received a gold medal in the 2022 R&D 100 awards program announced Aug. 22 by R&D World Magazine.

Read more


Darling honored by Society of Research Administrators

Jul. 14, 2022—Vanderbilt's Heather Darling, PMP, has been selected as a Future of the Field honoree by the Society of Research Administrators International.

Read more


Crowe receives national award for COVID antibody research

Mar. 31, 2022—Vanderbilt's James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.

Read more


Technique hastens COVID-19 antibody discovery

Mar. 10, 2022—Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.

Read more


Research Staff Awards honor those who help drive science forward

Mar. 9, 2022—Laboratory and administrative personnel at Vanderbilt University Medical Center were honored March 4 for research excellence during the 18th annual Research Staff Awards Ceremony.

Read more


Pandemic leads to broader use of monoclonal antibodies

Feb. 17, 2022—Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.

Read more


Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness

Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.

Read more


Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more